Construct validity and responsiveness of the Colombian version of Skindex‐29

Abstract

Summary Background In recent years, the need for international, objective, patient‐reported outcomes measures has grown as international collaboration has increased. As most quality‐of‐life scales have been developed in English, there is a growing need to adapt them transculturally to obtain equivalence between the original instrument and the adapted scale. Objectives To assess the construct and convergent–discriminant validity and responsiveness of the Colombian version of Skindex‐29. Methods The cross‐sectional and longitudinal validity and responsiveness were tested in both healthy and dermatology patients. Construct validity was tested through a confirmatory factor analysis. The convergent–discriminant validity was assessed by examining the Spearman correlation coefficient. Change sensitivity was tested by means of the standardized response mean. The effect size and the minimum detectable change were also assessed. Results A total of 265 participants were included; 21·1% were healthy individuals, and 78·9% patients had either inflammatory or noninflammatory skin diseases. Confirmatory factor analysis showed an adequate comparative fit index and Tucker–Lewis index adjustment for the root mean square error of approximation. Convergent validity showed moderate correlations between the emotions, functioning and physical function or physical role domains. Discriminant validity showed low correlations between overall domains for both scales. Sensitivity to change at the first and third month showed effect sizes in global Skindex scores of 0·92 and 0·82, respectively. Conclusions The Colombian version of Skindex‐29 is a valid and clinically sensitive instrument, which can be used for clinical practice and for research to measure the impact of skin diseases on the quality of life of dermatology patients.

Cross-cultural adaptation into French and validation of the SCAR-Q questionnaire

“…The objective of our study was to translate the SCAR-Q instrument into French [8][9][10][11] using International guidelines issued by ISPOR (International Society for Pharmacoeconomics and Outcomes Research) and by WHO (World Health Organization) [12,13], then to test the reliability and validity of the translated version.…”

Responsiveness of quality‐of‐life measures in patients with peripheral vascular malformations: the OVAMA project

“…In a systematic review on measurement instruments used in patients with vascular malformations, we found no studies assessing responsiveness in this population or similar populations. Very little was found on the assessment of responsiveness of the SF‐36 and Skindex‐29 in other patient populations, and in the studies that we found, mostly outdated methods were used …”

Quality of life of cutaneous leishmaniasis suspected patients in the Ecuadorian Pacific and Amazon regions: a cross sectional study

“…Our study has some limitations: The Skindex-29 questionnaire has not been validated for use by parents for their children, but our data show no significantly different scores between the 0–12, 13–22, and 23–39 age groups, suggesting that it was valid to include all patients in the analysis [ 17 , 24 ]. Second, this study used the Spanish version of the Skindex-29 questionnaire as validated in Colombia [ 24 ]. Nevertheless, many of the included Amerindian patients were non-native Spanish speakers and questions were translated by the health professional or a translator.…”

“…The Skindex-29 questionnaire has been translated and validated in more than ten languages in North and South American, European, Asian, and African cultures [ 18 – 23 ]. This study applied the Spanish version, which was previously validated in Colombia [ 24 ].…”